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Pharmacokinetic and Pharmacodynamic
Char acterîzatio n of a Medium -Molecular -
Weight Heparin in Comparison with IJFH
and LMWH
Susanne Alban, Ph.D., t  Dieter Welzel, M.D., l  and H. Coenraad Hemker, Ph.D.2
ABSTRACT
Despite the well-established medical use of heparins, the question arises
whether the efficacy-safety ratio of the available heparins can still be improved. There-
{ore, a medium-molecular-weight heparin (MMWH), a new heparin with ^î average
molecular weight of 10.5 kDa and a narrow molecular weight range (9.5 to 11.5 kDa) was
developed. Its in vitro activities amount to 174.9 anti-factor Xa (aXa) U/mg and 170.0
antithrombin (aIIa) U/mg. In the presented randomized, double-blind, cross-over study
in healthy volunteers, the pharmacokinetics and pharmacodynamics of MMWH are
compared with those of an unfractionated heparin (UFH) and a low-molecular-weight
heparin (LryVMH; enoxaparin). After subcutaneous administration of 9000 aXa-U of
either heparin in 16 volunteers, the prolongation ofthe activated partial thromboplastin
time (aPTT), the aXa activity, and the aIIa activities were determined at 11 time points
spread over 24 hours after injection. The ex vivo analysis revealed striking pharmacody-
namic and pharmacokinetic differences between the three heparins. UFH had the lowest
bioavailability regarding the aPTl aXa, and aIIa activities. Enoxaparin exhibited only
low aIIa activity but the highest aXa activity. Unlike UFH and enoxaparin, MMWH
showed a high recovery of aIIa activiry which suggests that it combines the high potency
to inhibit thrombin that characterizes UFH with the high bioavailability of the LMWHs.
Consequently, substantially lower doses are needed to bring about effects comparable to
those ofUFH and LMWFI.
KEYWORDS: U nf ractionated hepari n, medi u m-molecu la r-weight hepa ri n, low-
molecular-weight  epar in,  pharmacokinet ics,  pharmacodynamics
Objectives: Upon completion of this article, the reader should O" rO," to (1)l ist some of the properties of a newly developed
medium-molecular-weight heparin as compared with unfractionated and low-molecular-weight heparins and (2) describe some of
the findings related to the pharmacokinetics andpharmacodynamics of the new compound
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Fo, ,rro.. than 60 years, unfractionated heparin
(UFH) has been the drug of choice in the prophylaxis
and treatment of thromboembolic disorders.l After rwo
decades of intensive research, low-molecular-weight he-
parins (LMWHs) became more and more important and
tend to replace UFH.1 They turned out to be at least as
safe and effective as UFH for the prevention and treat-
ment of venous thromboembolism and have been used
successfully in patients with unstable angina.2 Because of
their decreased propensity to bind to plasma proteins,3
endothelial cells,a and macrophages,l'3 LMWHs show
some pharmacokinetic advantages over UFH so that for
prophylaxis, once-daily subcutaneous (s.c.) application is
sufficient.
In view of the outcome of clinical studies,l's 116
benefit ofheparins in general has been doubtless proved.
Nevertheless, there is still need for further improvement
of antithrombotic strategies. Especially in high-risk pa-
tients, such as elderly or tumor patients, a high residual
incidence of thromboembolic complications is observed
despite prophylactic measures. However, the established
prophylactic regimens with the available heparins can
hardly be improved. An increase in the dose is generally
associated with a higher bleeding risk.a
Because of this unsatisfactory situation, an impor-
tant focus of research is the development of new an-
tithrombotics, different from heparin.6'7 But the ideal
drug has not yet been discovered. A1l of them have the
imminent risk of inducing bleeding. Due to the key func-
tions of thrombin in thrombogenesis, the control of
thrombin generation and thrombin action represents an
important target.6 One strategy is the design of specific
factor Xa (FXa) and irreversible or reversible thrombin
inhibitors such as fondaparinux, hirudin, and melaga-
6x1.8-10 Irreversible inhibition of thrombin primarily acts
as an inhibitor of the thrombin-mediated positive feed-
back activation and thus retards thrombin generation, but
it is ultimately unable to prevent the explosive appearance
of thrombin.ll,r2 [1 concentrations that approach those
of (pro-)thrombin potentially available, the danger of too
much inhibition and hence of bleeding is imminent. Re-
versible inhibitors theoretically can never inhibit throm-
bin completely and therefore may offer a broader thera-
peutic window than irreversible inhibitors do. In contrast
to the direct thrombin inhibitors, FXa inhibitors do not
delay but efficiendy decrease thrombin generation as
shown in whole blood.11 However, on the basis of anti-
FXa (aXa) activity, about 20-fold higher concentrations
are required for an effect similar to that of heparin. This
is suggested to be due to the six times higher plasma con-
centrations of FX compared with F[ so that 9070 inhibi-
tion of FXa is required to obtain just 500/o inhibition of
the thrombin-generating prothrombinase.13
In contrast to this, heparin delays as well as de-
creases thrombin generation in whole blood.11 Heparin
inhibits both thrombin and FXa by catalyzing their in-
activation by antithrombin (AT). For the antithrombotic
activity, the inhibition of FXa, however, has proved to be
of minor importance, as can be expected for the reasons
mentioned earlier.la In addition to its AT-dependent an-
ticoagulant actions, heparin releases tissue factor path-
way inhibitor (TFPI) from endothelium into circulating
blood.15 This endogenous coagulation inhibitor acts
synergistically with heparinl6 and is supposed to con-
tribute to the overall antithrombotic activity of hepa-
rin.17,18 A further advantage of heparin is its manifold
additional biological activities.le At present, these ac-
tions are discussed as possibly supporting the therapeu-
tic benefit of heparin (e.g., as found in tumor patients).2o
For these reasons, it is worth asking whether
there is any option for improving the benefit-risk ratio
ofheparin.
Heparin is a polydisperse mixture of glycosami-
noglycans with molecular weight (MW) ranging from 5
to 40 kDa and an ^ vefage MW of 13 kDa showing great
structural complexity.le'21 To exhibit AT-mediated anti-
coagulant activity, the heparin molecules must contain a
specific AT-binding pentasaccharide sequence.22 The
percentage of this so-called high-affinity material varies
and is in general related to the average MW. It ranges
from about 5070 in UFH to 10026 in some rypes of
LMWFI.12 Only molecules consisting of more than 17
monosaccharides (>5.4 kDa) are able to inactivate both
FXa and thrombin. Accordingly, the high-affinity ma-
terial is subdivided into below the critical chain length
material (BCLM) showing only aXa activity and above
the critical chain length material (ACLM) with aXa as
well as aIIa activity. A special class of heparin molecules
is those with high MW (about > L3 kDa), which are ab-
sent in LMWH and are postulated to be responsible for
the low bioavailabiliry of UFH administered s.c. and the
induction of bleeding. For the mobilization of TFPI,
heparin does not require the AT-binding site,23 but this
action of heparin is strongly dependent on its MW.24
Based on these facts and on the knowledge thaf
the aXa activity of heparin does not contribute sig-
nificantly to its antithrombotic efftcacy,ra the available
LMWHs may not represent the optimal heparin. Al-
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though their bioavailability after s.c. administration is
high compared with UFH, their specific anticoagulant
activities, especially their aIIa activity, are lower. A hep-
arin with a relatively high MW but lacking the exrra
long heparin chains might combine the potent antico-
agulant action of UFH with the high bioavailability of
the LMWHs and maintain a pronounced TFPl-releas-
ing effect. We therefore developed a heparin with a
narow MW distribution around 10.5 kDa (MMWH).
In animal experiments, it proved to be more efficient
and safer than UFH and LMWH (J. Fareed et al, un-
published data, 1999). In the present srudy we com-
pared the pharmacokinetics and pharmacodynamics of
MMWH with those of an UFH and a LWMH after
s.c. administration in healthy volunteers.
MATERIALS AND METHODS
Heparins
Three different heparins were investigated: UFH
(Liquemin@ N, Hoffrnann-LaRoche AG, Basel, Switzer-
land), MNIWH (provided by Biochemie GmbH,
Schaftenau, Austria), and enoxaparin (Clexane@, Aventis
Pharma, Frankfurt, Germany).The three heparins are iso-
lated from porcine intestinal mucosa and are used as so-
dium salts. The production methods, the MW distribu-
tions, and the specific dG and aIIa activities are shown in
Tâble 1. Prefrlled glass syringes containing 9000 aXa-U of
either heparin were used for s.c. injection.
Subjects
Sixteen healthy normolipemic male students at the
University of Regensburg of mean age 25.9 + 3.3 years
(mean t SD, range 18-30 years), mean body weight
79.8 -r t2.t kg (range 60.0-95.0 kg), mean height
181.6 + 9.0 cm (range 167-198 cm), and mean BMI
24.1 -r 2.7 kg/mz (range 20.9-29.3 Wm2) were re-
cruited. All subjects provided written informed consent.
Volunteers were healthy as determined by med-
ical history, physical examination, blood pressure mea-
surements, hepatitis and human immunodeficiency
virus serologies, and routine biochemical, hematologi-
cal, and hemostatic tests including platelet counts, acti-
vated partial thromboplastin time (aPTT), and pro-
thrombin time. They neither suffered from any local or
general hemorrhagic diathesis nor had any previous
thrombotic disease. There was no contraindication for
the application of heparin. No other medications were
taken for 4 weeks before study entry and during the
trial. On the days of pharmacokinetic profiling, subjects
were given a scheduled standardized diet. They were
not allowed to consume alcohol or caffeine-containing
products within 48 hours of drug administration and
were asked to avoid strenuous physical exercise. One
week after the last treatment period, all routine bio-
chemical tests were redone, resulting in no significant
changes compared with the prestudy examinations.
Study Design
The study protocol was approved by the local Ethics
Committee (Ethikkommission der Bayerischen Atzte-
kammer) and was performed in accordance with the
Declaration of Helsinki and with European Commu-
niry Guidelines for good clinical practices.
The study was designed as a monocentric, ran-
domized, double-blind, three-period cross-over trial.
According to the randomization scheme, each volunteer
was given a single s.c. injection of 9000 aXa-U of either
heparin. A l-week washout period followed each hepa-
rin administration.
Venous blood for the determination of oharma-
cokinetic profiles was collected by clean venipuncture
(discarding the first 2 mL of blood) through an 18-
Table I Characterization of theThree Heparins Compared inThis Study
UFH
(Liquemino) MMWHCharacteristics
Enoxaparin
(Clexaneol
Production method.
Average MW (kDa)*
aXa-U/mgs
alla-U/mgr
aXa-l alla activity ratio
1 3 0
(3 0-30 0)
15 90
159  0
1 0 0
Mild isoamylnitr i te
degradation/
G PC-f ract ionation
1 0 5
(9  5-11  5)T
174 I
170 0
1 0 3
Benzylat ion/
B-el imination
A A
(3 5-5 5)+
100 0
263
3 8 0
*As declared by the manufacrurer
T90o/o (m/m) of  hepar in chains have MW between g S and 11 5 kDa
+90% (m/m) of  hepar in chains have a MW < 10 0 kDa
sThe speci f ic  aXa and al la act iv i t ies were measured according to the European Pharmacopoiea
using the 4th lnternat ional  Standard for  Hepar in (1983) or  the 1 st  Internat ibnal  Standard for
LMWH (Nat ional  Inst i tute for  Bio logical  standards and contro l ,  London) as reference.
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gauge indwelling cannula (Vasofix@ Braunùle@ and
I4urrdti.tt, B. Braun Melsungen, Melsungen, Ger-
was prepared by centrifugation at 3000 g for 20- minutes
"t 
f i"Cl transferred into cryovials in aliquots of 0'5 mL,
frozeninliquid nitrogen, and stored ar -70"C until fur-
ther analysis.
APTT, axa, and aIIa ActivitY
The validity of each determination was checked by par-
allel controls with control plasma, the Fourth Interna-
tional Standard for heparin (1983), or the First Interna-
tional Standard for LMWH (National Institute for
Biological Standards and Control, London, UK)'
The aPTT activity was determined as prolonga-
tion of the baseline clotting time using a commercial kit
according to the instructions of the manufacturer (APTT
Micro Kieselgur, Instrumentation Laboratory)'
Plasmà dfu and aIIa activities were measured by
amidolytic assays using reagents from Chromogenix AB
(Mohàal, Sweden). Plasma samples diluted with AT
containing TRIS buffer were incubated with bovine
FXa and bovine thrombin, respectively' After mixing
with the chromogenic substrates 52222 and 52238, re-
spectively, the amidolysis was recorded at 405 nm for
120 seconds. The resulting absorbance was calculated as
oercent inhibition of FXa and thrombin' respectively' by
-eans of th. baseline absorbance. The lowest sensitivity
was 0.02 lJ/mL for both assays. The intra- and interday
relative standard deviations were less than 5olo'
Pharmacokinetic AnalYsis
The noncompartmental pharmacokinetic parameters
were evaluated by standard methods'26 The maximum
the same gravimetric dose (1 mg), the AUCo-ron values
were divided by the given gravimetric heparin dose, that
is, 56.6 mg MMWH, 51.5 mg UFH, and 90'0 mg
enoxaparln.
The time courses of activities after s'c' adminis-
tration of the three different heparins were best de-
scribed by a biexponential curve (Bateman function)
fitting. The aPParent invasion half-life t1l2,n was calcu-
lated from the ascending part of the plasma concentra-
termined using the fitted plasma concentration-activity
curves. MRT Jorresponds to the time at which 63'2o/o f
the total AUC is uchie'oed and is calculated as MRT =
AUMC/AUC, where AUMC is the area under the first
moment curve.28
Statistical AnalYsis
All results were determined as mean + SD (standard
RESULTS
Clinical Observations and Safety profile
All volunteers completed the study. The s'c' administra-
tion of 9000 aXa-U of MMWH, UFH, and enoxaparin
was well tolerated. No adverse events or bleeding com-
plications were observed during the experiments and at
the poststudy examination.
APTT, aXa, and alla ActivitY
Mean plasma activities in the aPTl aXa, and aIIa as-
,uy, ,, 
" 
function of time after s'c' administration of the
three heparins are illustrated in Figure 1' MMWH was
-o." .ftfi.r.ious than enoxaparin and UFH in the
aPTT and especially in the aIIa assay' In the aXa assay,
enoxaparin pio.ted to be the most active' followed by
MMWH and {inally UFH with the weakest effect'
The different anticoagulant potencies of the three
heparins become obvious from the AUC. 24h of the ac-
tivities in the three assays. They were calculated on the
basis of the respective effects, that is, the prolongation
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of clotting time and inhibition of FXa and thrombin
(Fig. 2). According to the varying order of the AUC0_24h
values in the three assays, the three heparins differed
significantly not only in their pharmacokinetic but also
in their pharmacodynamic profiles. The mean AUC0_24h
values of MMWH were generally higher than those of
UFH: 1.48 times in the aPTT 2.00 times in the aXa,
and 7.77 times in the aIIa assay. In the aPTT and the
aIIa assay, it was also more active than enoxaparin (1..23
times and 1.52 times, respectively); in the aXa assay, its
activity was 2.34 times lower than that of enoxaparin.
Compared with UFH, enoxaparin showed 4.69 times
higher aXa activity, but its effects in the aPTT and aIIa
assay were only moderately better.
8 1 0 1 2 1 4 1 6 1 8 2 0 2 2 2 1
time [h]
8  1 0 1 2 f l 1 A 1 8 2 0
time [h]
2 4 10  12  14
time [h]
Figure 1 Time-dependent mean (n = t6, + SD) coagulat ion
l imes (seconds) in aPTT (aPTT activi ty) and inhibit ion (%) of FXa
(aXa activi ty) and thrombin (al la act ivi ty) measured in the
plasma samples obtained after single s c administrat ion of
9000 aXa-U of MMWH, UFH, and enoxaparin
Similar tendencies as for the AUCo_ron were found
for the effect-based c-o, but the differences between the
three heparins were smaller (Table 2). An exception was
the c-o of enoxaparin in the aPTT. In contrast to its
AUC0_24h, it was not only lower (43o/o) than that of
MMWH but also lower than that of UFH (25%o).
Comparison on aWeight Basis
According to the usual practice, equal doses of aXa ac-
tivity of each heparin were administered. However,
based on the specific activities (aXa-Ulmg) of the three
heparins, these correspond to 51.5 mg MMWFI, 56.5
mg UFH, and 90 mg enoxaparin. When compared on a
weight basis, the AUC0_24h and c-* differences between
MMWH and UFH increased by about 100/o in favor of
MMWH and those with enoxaparin by as much as 750lo
(F ig .3 ) .
Pharmacokinetic Parameters
We determined the pharmacokinetic parameters t**,
t7/2inu, t1l2., (minutes), and MRT (hours) (Table 2).
The differences in these parameters are less obvious
than those in c-oi nevertheless, MMWH differed sig-
nificantly from either or both UFH and enoxaparin in
aXa. aIIa. and aPTT activities.
Its t-o values of about 4 hours approximately
corresponded to those of Lry\MH and were on average
300/o longer than those of UFH.
The t7/2, 
"varied 
between about 1 and 2 hours.
Due to its high c-*, the t7/2 ^"values of MMWH were
longer than those of UFH, but the appearance of its ac-
tivities was faster (Fig. 1). The aPTT and aIIa activiry
of MMWH also appeared faster than those of enoxa-
parin. However, in the aXa assay MMWFI showed the
fastest appearance as well as the shortest t..,. Whereas
the t7/2 ^, of MMWH did not differ significantly be-
tween the three assays, the t7/2r^" of UFH in the aPTT
was significantly shorter than those in the aXa and aIIa
assays and thetT/2.",of enoxaparin in the aIIa assaywas
significantly longer that those in the aPTT and the aXa
assay.
'Îhe t7/2.rvalues were generally longer than the
t1/2.nu ones, ranging between about 2 and 4 hours.
Those of MMWFI and UFH did not differ signifi-
cantly. But compared with enoxaparin, the t1l2", values
of MMWH in the aPTT and the aXa were signifi-
cantly shorter, whereas that in the aIIa assay was signif-
icantly longer. Comparing the different activities, the
aIIa activity of MMWH was eliminated significantly
more slowly than its aPTT and aXa activiry whereas in-
versely the aIIa activity of enoxaparin disappeared sig-
nificantly faster than both its aPTT and aXa activity.
In all three assays, the MRTs were shortest for
UFH and longest for enoxaparin. One exception was
14 60
oÈE 5 0
o
o 4 0
o)
o
8 3 0
s
: 8 0
o
9 6 0
c
o 4 0
X
Ero(U
s
I
-o
c
_o
E
I
c
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APTT activity aXa actlvlty alla activity
MùfWFl UFH enoxaparin Mklwtl UFH enoxaparin MlMftl UFHenoxaparin
Figure 2 Mean (n = 16, + SD) AUCo_24h for the aPTI aXa, and al la act ivi t ies after single sc administrat ion of 9000 aXa-U c
MMWH, UFH, and enoxaparin The AUCo_ron values are based on the respective ffects, that is, the prolongation of the aPTT and th
percent inhibit ion of FXa and thrombin. The p values represent the signif icance level obtained by pairwise comparisons between th
three heparins (signif icant dif ferences: p < 05) in each case
f
o
c
I
è
C)
f
the MRT of MMWH in the aIIa assay, which was not
only longer than that of UFH but also somewhat longer
than that of enoxaparin.
DrscusstoN
Hemker and colleagues13,14 surmised that the main an-
tithrombotic ^ctivrty of a heparin would be localized in
molecules with a definite aIIa activity and yet small
enough to have high bioavailability. Moreover, experi-
ments demonstrated that the aXa activrty of heparin is
only a partial expression ofthe therapeutic potential an
that the antithrombotic effect improves with increasin
chain length of heparin fragments.3r3a
The new heparin that we tested, MMWH, ha
^î average MW of 10.5 kDa and a narrow MW rangt
In contrast to UFH, it does not contain molecules wit
MW > 15 kDa, which on good grounds can be thougl
to be responsible for hemorrhagic complications.l3 11
specific aXa and aIIa activities are 1070 higher tha
those of UFH. This indicates that during the produc
tion of MMWH the content of high-aflinity materir
Table 2 Pharmacokinetic Parameters* for Plasma aPTT, aXa, and alla Activity after
Single Subcutaneous Administration of 9000 aXa of MMWH, UFH, and Enoxaparint
aPTTActivity aXa Activity alla Activity
c-u, (s)t and (% inhibit ion)
MMWH
U F H
Enoxaparin
t-.* (min)
MMWH
U F H
Enoxaparin
t1l2rn" (min)
MMWH
U F H
Enoxaparin
t1l2", (min)
MMWH
U F H
Enoxaparin
MRT (h)
MMWH
U F H
Enoxaparin
2 2 . 5 ! 1 0 7  4 6 7 + 1 1 5  5 5 5 1 1 4 3
1 7 . 4 + 1 2 . 7 p 0 1 2 7  3 1  4 + 1 2 2 p 0 0 0 1  4 1  0 + 1 4 8 p 0 0 0 1
1 3 0 + 4 5 p 0 0 0 1  7 7 . 2 + 7 . 9 p 0 0 0 1  4 1 3 + 1 2 5 p 0 0 0 1
233 + 82
1 7 8 + 7 3 p 0 1 1 5
2 4 0 + 4 9 p 7 3 5 3
1 0 5  +  1 7
6 7  + 3 7  p  0 0 0 3
8 2 + 2 8 p 0 2 2 4
129 +  68
1 5 3 + 1 0 7 p . 7 7 5 3
2 2 5 + 1 2 6 p 0 1 8 7
116 + 24
9 1 + 2 6 p 0 0 5 7
8 9 + 2 4 p 0 0 3 7
13'7 * 28
1 1 5 + 4 0 p 2 3 7 8
252 t83 p 0001
9 9 1 3 6
84 +34 p 0631
1 2 2 t 2 2 p 0 0 8 2
171 + 59
1 4 0 + 6 4 p 0 5 7 2
1 3 4 + 2 9 p 0 2 3 9
218 + 43 221 + 46
171 + 46 p 0036 184 + 46 p 0081
221 + 36 p 8070 248 + 3l p 0588
8 6 8 + 1 8 2  9 4 8 + 1 6 8  9 9 5 1 1 6 1
7 . 9 5 + 2 1 2 p  1 6 5 6  8 0 0 + 2 1 4 p  0 0 1 3  8 5 3 + 2 . 0 7 p  0 0 9 4
9 7 4 + 2 . 1 1  p 0 4 6 1  1 1  2 7 + 0 9 6 p 0 0 0 2  9 5 0 + 2 . 8 8 p 4 0 1 0
*Data are presented as mean (n = 16) *  SD; Pvalues for  the compar ison between MMWH and UFH and
MMWH and enoxapar in,  respect ively,  are shown, P < 0 05 is  s igni f  icant
tBasis of  the calculat ion:  prolongat ion of  coagulat ion t ime
+Doses administered:  5 '1 5 mg MMWH, 56 5 mg UFH, 90 0 mg enoxapartn
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APTT activity aXa activity alla activity
MtvtWH UFH enoxaparin MMWIi UFH enoxaparin MMWFI UFHenoxaparin
Figure 3 Mean (n = '16, + SD) AUC. 24h adjusted to the same gravimetric dose (1 mg) of each administered heparin (51.5 mg
MMWH, 56 5 mg UFH, 90 0 mg LMWH) for the aPTI aXa, and al la act ivi t ies after single s c administrat ion of 9000 aXa-U of
MMWH, UFH, and enoxaparin The AUCo 
,on values are based on the respective ffects, that is, the prolongation of the aPTT and the
oercent inhibit ion of FXa and thrombin
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remains constant. Hence there is no destruction of the
AT binding pentasaccharide sequence, that is, loss of
high-affinity binding sites. On a weight basis, the spe-
cific aXa activity of MMWH is 7.75 that of enoxaparin;
on a molar basis, it is 4 times higher, which is a natural
consequence ofthe fact that upon breakdown ofheparin
molecules to half their MW the total number of mole-
cules doubles but the number of high-affinity molecules
does not increase. Whereas only a small part of the
high-affinity material of LMIMH exceeds the critical
chain length of 17 monosaccharides that makes zlla ac-
tivity possible, MMWH exclusively consists of such
ACLM. Consequently, its specific aIIa activity is as
high as its specific aXa activity.
A heparin fraction with an ^ verage MW of about
7.5.\<Da would also have an aXa/alIa activity ratio of
1.0. But as a result of the stronger degradation its spe-
cific activities would be lower than those of MMWH.
Also, at lower MW less of the TFPl-releasing effect of
heparins is retained.2a There are several pharmacologi-
cal reasons why a MW in the range 9 to 12 kDa must be
considered optimal. The bioavailability after s.c. admin-
istration of heparin decreases with increasing MW.3s
High-MW molecules are more readily neutralized by
platelet factor 4 (Pn+;s6 and increase the tendency of
heparin to induce heparin-induced thrombocltopenia
(HI1;.:z'ss Finally, the risk of bleeding should be re-
duced,3o In particular, high-MW molecules with low
AI af{inity interfere with platelet function and were
shown to contribute signi{icantly to hemorrhage but
less to the in vivo antithrombotic activity.3e'ao The ab-
sence of molecules larger than 15 kDa in MMWH and
a high content of high-affinity material are two condi-
tions that may contribute to improved safety.
In the present study, the pharmacokinetics and
pharmacodynamics of MMWH were compared with
those of an UFH and enoxaparin. Both the aPTT and
the aXa and aIIa assays demonstrated that MMWH
shows more favorable characteristics than either UFH
or enoxaparin. After s.c. administration the bioavail-
ability of MMWH, as judged from the AUC*rrn, is
much better. This is more evident in the pharmacoki-
netic parameters, that is, in the aXa and aIIa activities,
than in the pharmacodynamic effect on the aPTT.
Comparison of the aPTT data with the inhibition of
thrombin generation shows that this must be largely
attributed to the aPTT being only a poor indicator of
the pharmacodynamic effect of heparin (manuscript in
preparation).
Based on the results ofthis study, halfthe dose of
MMWH is sufficient to obtain aXa and aIIa activities
similar to those after s.c. administration of UFH. Thus,
nonspecific anticoagulant effects can be reduced while
the specific effects are maintained, which according to
Holmer et a130 and Ockelford et a13e would imply an im-
proved benefit-risk ratio.
With the exception of c-* of enoxaparin in the
aXa assay, the c-* also followed the trend of AUCo-ra,
but the differences were smaller. This means that the
high AUC is not obtained by dangerously high peak
concentrations of the drug. On reducing the dose of
MMWH to a level with c-* similar to that of UFH and
enoxaparin, the corresponding AUCo-rrn would still be
higher than those of UFH and enoxaparin.
The comparison of further pharmacokinetic pa-
rameters confirmed that MMWFI differs from UFH as
well as LMWH. It can be considered as an advantage
that the tL/2,, and the MRT of the aIIa activity of
MMWH are significantly longer than those of its
aPTT activity. Consequently, in contrast to UFH and
enoxaparin, the most important pharmacological action
is the longest detectable in plasma.
In the present study, we limited ourselves to re-
porting the data obtained with the classically used as-
says for the heparin determinations to facilitate com-
parison with publications on other heparins. According
to the pharmacokinetic data, MMWH might be suit-
able for s.c. administration once daily. Further, the re-
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sults of this study suggest that the appropriate doses
may be lower than those of LMWH and UFH; this
conclusion can obviously be substantiated only by dose-
finding studies.
After s.c. administration of 9000 aXa-U each,
MMWH was shown to release 43o/o and 590lo more free
TFPI (AUCs-2ah) than UFH and enoxaparin.2a This
may be considered an additional asset' It is probably
caused by a favorable compromise between the increase
of TFPl-releasing potency with MW and the increase
of bioavailabitity with decreasing MW.
In conclusion, MMWH is a heparin with an av-
erage MW between that of UFH and LMWH and
with a particularly narrow MW distribution. In this
way. it contains neither molecules with MW > 15 kD, as
are characteristic of UFH, nor short-chain molecules
(BCLM) exhibiting aXa activity only. It thus combines
the favorable bioavailability of LMWH with the high
specific anticoagulant activity of UFH. There are good
.."rorrc to believe that MMWH is the "pure" specifi-
cally acting working core ofany natural heparin PrePa-
ration. It may therefore be more efficient and possibly
also safer than other heparins, especially because sub-
stantially lower doses (on a weight and a molat basis)
are sufficient to bring about effects comparable to those
ofUFH and LMWH.
ACKNOWLEDGMENTS
We are grateful for financial suPport by the Novartis-
Stifrung ftir Therapeutische Forschung, Nuremberg,
Germany.
REFERENCES
1. Hirsh J, Warkentin TE, Shaughnessy SG, et al' Heparin and
low-molecular-weight heparin: mechanisms of action, phar-
macokinetics, dosing considerations, monitoring, efficacy, and
safety. Chest 2001;119(Suppl 1):645-945
2. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM,
Cheah G. A meta-analysis comparing low-molecular-weight
heparins with unfractionated heparin in the treatment ofve-
nous thromboembolism: examining some unanswered ques-
tions regarding location of treatment, product type, and dos-
ing frequency. Arch Intern Med 2000;160:1881-1888
3. Young E, Wells P, Holloway S, Weitz J, Hirsh J Ex-vivo and
in-vitro evidence that low molecular weight heparins exhibit
less binding to plasma proteins than unfractionated heparin'
Thromb Haemost 19 9 4;7 1':300-304
4. Ba:lzLr I Molho P, Tobelem G, Petitou M, Caen J. Binding
and endocytosis ofheparin by human endothelial cells in cul-
ture. Biochim Biophys Acta 1985;845:196-203
5. Sarret M, Kher A, Toulemonde F. Low Molecular Weight
Heparin Therapy. 1st ed. New York Marcel Dekker; 1999
6. Hirsh J, Weitz JI. New antithrombotic agents' Lancet !999;
353:1431-1436
T.Weitz JI, Hirsh J: New anticoagulant drugs. Chest 2001;
119(Suppl 1):395-63S
bentham.orglcdtchdl-1/shen /shen.htm
10. Gustafsson D, Nystrom J, Carlsson S, et al. The direct throm-
bin inhibitor melagatran and its oral prodrug H 376/95'ln-
testinal absorption properties, biochemical and pharmacody-
namic effects. Thromb Res 2007;70t:17 t-78I
11. Lindhout T, Blezer R, Hemker HC. The anticoagulant
mechanism of action of recombinant hirudin (CGP 39393) in
plasma. Thromb Haemost L990;64:464-468
!2. Herault JP, Bernat A, Gaich C, Herbert M. Effect of new
synthetic heparin mimetics on whole blood thrombin genera-
tion in vivo and in vitro in rats. Thromb Haemost 2002;87:.
238-244
13. Béguin S, Welzel D' Al Dieri A, Hemker HC' Conjectures
and refutations on the mode of action of heparins' Haemosta-
sis 1999;29:770-788
14. Béguin S, Lindhout T, Hemker HC. The mode of action of
heparin in plasma. Thromb Haemost 1988;60:457-462
15. Sandset PM, Abildgaard U, Larsen ML' Heparin induces
release of extrinsic coagulation pathway inhibitor (EPI)'
Thromb Res 1988;50:803-813
16. Abildgaard U, Lindahl AK, Sandset PM. Heparin requires
both antithrombin and extrinsic Pathway inhibitor for its
anticoagulant effect in human blood. Haemostasis 1991.2I:
25+-257
17. Valentin S, Ostergaard P, Kristensen H, Nordfang O' Syner-
gism berween full length TFPI and heparin: evidence for
1FPI 
"r 
an important factor for the antithrombotic activity of
heparin [letter]. Blood Coagul Fibrinolysis 1992;3:221-222
18. Abildgaard U. Heparin/low molecular weight heparin and
tissue factor pathway inhibitor. Haemostasis 1993;23(Suppl
1):103-106
19. Linhardt RJ, Toida T. Heparin oligosaccharides: new ana-
logues development and applications. In: Witczak ZJ,
Nieforth KA, eds. Carbohydrates in Drug Design' NewYork:
Marcel Dekker ; 1997 :277 -347
20. Zrchzrisl<t LR, Ornstein DL. Heparin and cancer' Thromb
Haemost 1998;77 :289-297
21. Linhardt RJ, Loganathan D, al-Hakim A, et al. Oligosaccha-
ride mapping of low molecular weight heparins: structure and
activity differences. J Med Chem 1990;33:7639-1645
Characterization of the binding between tissue factor path-
way inhibitor and glycosaminoglycans. Thromb Res 1994;75:
173-183
24. Alban S, Gaslpar R. Plasma levels of total and free tissue factor
pathway inhibitor (TFPI) as individual pharmacological para-
meters of various heparins. Thromb Haemost 2001;85 :824-829
25. Witt I, Beeser H, Mùller-Berghaus G. Minimalanforderun-
gen zur Gewinnung von Citratplasma fiir hâmostaseologische
Analysen. Lab Med !995;I9:I43-I45
26. GrbaJdi M, Perrier D. Pharmacokinetics. 2nd ed' New York:
Marcel Dekker; 1992
27. Rowland M, Tozer TN. Clinical Pharmacokinetics' Con-
cepts and Applications. Philadelphia: Lea & Febiger; 1989:
459-461
CHARACTERIZATION OF MEDIUM MOLECULARWEIGHT HEPARIN/ALBAN ET AL 377
28. Yamaoka K, Nakagawa I Uno T. Statistical momenrs in
pharmacokinetics. J Pharmacokinet Biophar m 797 g;6:5 47 -
558
29. Generica, Version 2.0, Prof. Dr R. Zincke, Coesfeld, Ger-
many, 1989
30. Holmer E, Mattsson C, Nilsson S. Anticoagulant and an-
tithrombotic effects of heparin and low molecular weight
heparin fragments in rabbits. Thromb Res 1982;25:4i5-
485
31. Ockelford PA, Carter CJ, Mitchell L, Hirsh J. Discordance
between the anti-Xa activiry and the antithrombotic activiry
in an ultra-low molecular weight heparin fraction. Thromb
Res 1.982;28:401-409
32. Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L,
Lindahl U. Effects of heparin oligosaccharides with high af-
finity for antithrombin III in experimental venous thrombo-
sis. Thromb Haemosr 1,982;47 :244-248
33. Bergqvist D, Nilsson B, Hedner U, Pedersen pC, Osrereaard
PB. The effect of heparin fragments of different molecular
weights on experimental thrombosis and haemostasrs.
Thromb Res 1985;38:589-601
34. Thomas DP, Merton Rtr, Gray E, Barrowcliffe TW. The rel-
ative antithrombotic effectiveness ofheparin, a low molecular
weight heparin, and a pentasaccharide fragment in an animal
model. Thromb Haemost 7989;6I:204-207
35. Hoppensteadt DA,Jeske W, Ahsan A, WalengaJM, FareedJ.
Biochemical and pharmacologic profile of defined molecular
weight fractions of heparin. Semin Thromb Hemost 1993;
79:72-19
36. Samama MM, Bara L, Gerotziafas GT. Mechanisms for the
antithrombotic activity in man of low molecular weight he-
parins (LMWHs). Haemostasis 7994;24:105-717
37. Greinacher A, Aiban S, Dummel Y, Franz G, Mueller-
E,ckhardt C. Characterization of the structural require-
ments for a carbohydrate based anticoagulant *itÀ re-
duced risk of inducing rhe immunological type of
heparin-associated thrombocytopenia. Thromb Haemost
7995;74:886-892
38. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced
thrombocytopenia in patients treated with 1ow molecular
weight heparin or unfractionared heparin. N Engl J Med
1,995;332:7330-7335
39. Ockelford PA, Carter CJ, Cerskus A, Smith CA, Hirsh J.
Comparison of the in vivo hemorrhagic and antithrombotic
effects of a low antithrombin-Ill affiniry heparin fraction.
Thromb Res 1982;27 :679-690
40. Cade JII Buchanan MR, Boneu B, et al. A comparison of the
antithrombotic and haemorrhagic effects of làw molecular
weight heparin fractions: the influence of the method of
preparation. Thromb Res 7984;35:673-625
